Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx Pharmaceutical Inc.

In a report released yesterday, Benjamin Burnett from Wells Fargo maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $65....

Wells Fargo Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of ...

Evercore ISI Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Tactical Resources Corp. ( ($TSE:RARE) ) has shared an update. Tactical Resources Corp. announced a share consolidation in preparation for a busine...

Tactical Resources Announces Share Consolidation Ahead of Business Combination

Tactical Resources Corp. ( ($TSE:RARE) ) has issued an announcement. Tactical Resources Corp has announced the effectiveness of its registration st...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RARE	$34.58	+1.32%	721.61K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RARE	$34.58	+1.3%	721.61K
3
4
5
6

RARE

RARE

Get Ultragenyx Pharmaceutical Inc. Data in Excel

Get Ultragenyx Pharmaceutical Inc. Data in Excel